Affects Oracle Life Sciences Empirica Signal, a widely deployed enterprise app; high risk of data theft/modification across environments.
CVE-2026-21997
HTTP-accessible privilege escalation in Oracle Life Sciences Empirica Signal.
Is CVE-2026-21997 being exploited?
Not confirmed. CVE-2026-21997 does not appear in CISA's Known Exploited Vulnerabilities catalog, which records only exploitation that has been observed and reported publicly. That is evidence of absence of a report, not evidence the flaw is unattacked. EPSS currently estimates a 0.20% probability of exploitation in the next 30 days.
How severe is CVE-2026-21997?
CVE-2026-21997 is rated High with a CVSS score of 8.5. Severity describes how bad exploitation would be, not how likely it is: pair it with exploitation evidence before deciding what to patch first.
Is there a patch for CVE-2026-21997?
Yes. A fix has been recorded for CVE-2026-21997. The vendor advisory is the authority on the exact fixed version — apply it from there rather than from a summary.
What does CVE-2026-21997 affect?
CVE-2026-21997 affects Oracle Life Sciences Empirica Signal 9.2.1-9.2.3 (Common Core). Confirm the exact affected versions against the vendor advisory before deciding you are exposed.
What should I do about CVE-2026-21997?
Restrict HTTP access; monitor for exploitation; apply patch when released.
Exploitation status reflects CISA's KEV catalog as we last synced it. Check the catalog directly.
Low-priv attacker over HTTP can create/modify/delete data or read data in Empirica Signal.
Patch when possible
- affected>= 9.2.1 and <= 9.2.3
As published in the CVE Program record. A version outside these ranges is not a statement that it is unaffected — vendors sometimes understate a range, and distribution-backported builds carry upstream numbers that do not reflect what was patched into them.